1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,004 | 0,004 | 08:53 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.10. | Aptamer Group PLC - Full Year Results for the 12mths to 30 June 2026 | 1 | RNS | ||
| 07.10. | Aptamer Group PLC - Notice of Results, Analyst & Investor Presentation | 1 | RNS | ||
| APTAMER GROUP Aktie jetzt für 0€ handeln | |||||
| 20.08. | Aptamer Group PLC - Appointment of Joint Corporate Broker | 1 | RNS | ||
| 14.08. | Aptamer Group PLC - Director Fee Shares and Grant of Options | - | RNS | ||
| 13.07. | Aptamer Group PLC - Trading Update | 1 | RNS | ||
| 09.07. | Aptamer Group moves into Ebola diagnostics | 1 | The Armchair Trader | ||
| 08.07. | Aptamer Group Begins Development of Rapid Test for Bundibugyo Ebola | 2 | Contract Pharma | ||
| 08.07. | TRADING UPDATES: Brave Bison earnings jump; Aptamer begins Ebola work | 1 | Alliance News | ||
| 08.07. | Aptamer Group PLC - Aptamer initiates Ebola diagnostic test programme | 1 | RNS | ||
| 25.06. | Aptamer Group PLC - Programme and technical development update | 1 | RNS | ||
| 08.06. | Aptamer launches funded folic acid fortification testing programme | 4 | Sharecast | ||
| 08.06. | Aptamer Group PLC - Rapid testing programme for fortified foods | 1 | RNS |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 42,820 | -0,02 % | Finanzinvestor EQT will Qiagen für über 9 Milliarden Euro kaufen - Agentur | DJ Finanzinvestor EQT will Qiagen für über 9 Milliarden Euro kaufen - Agentur
DOW JONES--Der Finanzinvestor EQT will einem Agenturbericht zufolge den Diagnostikspezialisten Qiagen übernehmen. Wie... ► Artikel lesen | |
| DISC MEDICINE | 75,94 | -0,08 % | Jefferies raises Disc Medicine stock price target on drug opportunity | ||
| ENLIVEN THERAPEUTICS | 41,820 | 0,00 % | H.C. Wainwright hebt Kursziel für Enliven Therapeutics auf 73 $ an | ||
| CG ONCOLOGY | 62,24 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| TANGO THERAPEUTICS | 26,990 | +0,04 % | Tango Therapeutics (TNGX) Has Striking Pancreatic Cancer Data. How Much Is Priced In? | ||
| PRAXIS PRECISION MEDICINES | 256,86 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,840 | 0,00 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| ABSCI | 10,040 | 0,00 % | Absci Corporation: Absci Announces Preliminary Details for Phase 2 STORYLINE Trial of AI-Designed Antibody ABS-201 for Endometriosis | Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial... ► Artikel lesen | |
| NURIX THERAPEUTICS | 26,000 | -0,08 % | H.C. Wainwright raises Nurix stock price target on strong revenue | ||
| SUMMIT THERAPEUTICS | 15,825 | -0,03 % | Akeso, Inc.: Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer | Becomes the 7th International Registrational Clinical Trial for Ivonescimab
Clinical Trial Site Activations in the United States Expected to Begin Q4 2026
HONG... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 19,120 | 0,00 % | ArriVent BioPharma, Inc. - 8-K, Current Report | ||
| RAPPORT THERAPEUTICS | 25,060 | 0,00 % | Jones Trading raises Rapport Therapeutics price target on pipeline potential | ||
| ARCUS BIOSCIENCES | 19,080 | -0,03 % | Arcus Biosciences prices $250 million stock offering at $17.50 | ||
| KYMERA THERAPEUTICS | 112,56 | -0,06 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,640 | 0,00 % | Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast |
APTAMER GROUP PLC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,002 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu APTAMER GROUP PLC finden Sie auf Wallstreet Online.